ERBB2 and ductal breast carcinoma in situ: Since ductal carcinomas in situ (DCIS) express HER2 prior to a transition to an invasive phenotype, there may be clinical benefit to treating BC with HER2-targeted agents even in the absence of HER2 gene amplification.